Date: 2010-01-10
Type of information: Nomination
Compound:
Company: Bind Biosciences (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 11, 2010, Bind Biosciences announced the appointment of Scott Minick as President and CEO. Mr. Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of Sequus Pharmaceuticals/Liposome Technology Inc., where he led the company during its 1995 FDA approval and successful commercial launch of the leading oncology drug, Doxil® (liposomal doxorubicin). Sequus was subsequently acquired by Alza for $580 MM.
Financial terms:
Latest news: